Allied Minds (LSE: ALM), a diversified holding company focused on venture creation within the life science and technology sectors, today announces that its subsidiary, Precision Biopsy, has raised an additional $5.0 million in new equity from the sale of additional Series A Preferred shares to investor Woodford Investment Management, as the company continues its global commercialization strategy for its ClariCore™ Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures.
Precision Biopsy Expands the Clinical Trial of Its ClariCore™ Biopsy System in Prostate Cancer Patients
Precision Biopsy announced that its application for an Investigational Device Exemption (IDE) was approved by the U.S. Food and Drug Administration (FDA), allowing the company to expand its clinical trial for the ClariCore™ Biopsy System by enrolling prostate cancer patients in the Transrectal Ultrasound (TRUS) and MR/Fusion arms of its study.
Prostate cancer remains a major health concern for men of North America and Europe. In 2016, it is estimated that 180,890 men will be diagnosed with prostate cancer and 26,120 men will die from this disease in the United States alone. Disease is diagnosed by pathological examination of biopsy tissue obtained from patients suspected of having the disease.
Precision Biopsy Submits Investigational Device Exemption (IDE) Application to the FDA to Expand Clinical Trial of Its ClariCore™ Biopsy System in Prostate Cancer Patients
Precision Biopsy announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for permission to enroll patients in the Transrectal Ultrasound (TRUS) and MR/Fusion arm of the company’s study, expanding the scope of a clinical trial for its ClariCore™ Biopsy System in prostate cancer patients.
Precision Biopsy Raises $33.6 Million to Accelerate the Commercial Expansion of its ClariCore™ Biopsy System
Precision Biopsy announced that it successfully raised $33.6 million in new equity investments as the company embarks on a global commercialization strategy for its ClariCore™ Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures.
Precision Biopsy to Move Into New Bioscience 2 Building Next to the Anschutz Medical Campus of the University of Colorado This June
The Fitzsimons Redevelopment Authority (FRA) announced that Precision Biopsy will be the first commercial company moving into their new Bioscience 2 building this June. This custom-built space will allow Precision Biopsy to expand from the pre-built lab they occupied in Bioscience 1 as the company initiates a global commercialization strategy for its real-time tissue classification technology used in prostate biopsy procedures.
Precision Biopsy is pleased to announce that Amir Tehrani has joined as Chief Executive Officer to manage commercial expansion after the company successfully demonstrated the unique ability of its technology to accurately diagnose prostate cancer in patients in a Phase 1 clinical trial.